Pfizer manager doing time for insider trading


Amit Dagar was charged in June 2023 with trading ahead of a November 2021 announcement that Paxlovid had reduced hospitalisations and deaths in high-risk patients by 89%, which sent the shares surging. — Reuters

NEW YORK: A former Pfizer Inc statistician was sentenced to nine months behind bars for making more than US$200,000 by trading on confidential information before a key announcement about the drugmaker’s Covid-19 treatment Paxlovid.

Amit Dagar, convicted of securities fraud and conspiracy after a one-week trial in January, was sentenced on Tuesday in a federal court in Manhattan by US District Judge Andrew L. Carter Jr.

He was charged in June 2023 with trading ahead of a November 2021 announcement that Paxlovid had reduced hospitalisations and deaths in high-risk patients by 89%, which sent the shares surging.

He had asked for a sentence of probation or home confinement.

The case is part of an effort by Manhattan US Attorney Damian Williams to crack down on corporate crime including insider trading.

The charges were announced the same day as the case against a trio of investors accused of trading on secret information about the merger plans of Digital World Acquisition Corp, the blank check company that took Donald Trump’s social media startup public. — Bloomberg

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

GX Bank, CGC Digital to offer credit access up to RM150,0000 to MSMEs
Shell Malaysia to expand its Westport fuels terminal
Bursa Malaysia stays lower at midday following lack of progress at Trump-Xi summit
L&G launches Damansara Laverra development with RM752mil GDV
Censof unit to develop Islamic accounting system for FT Islamic council
Affin Bank records higher 1Q net profit of RM135.5mil
Local institutions extend buying streak on Bursa Malaysia
Hong Leong Bank to facilitate access to Bank Negara's SME Stabilisation Relief Facility
PIVB keeps 20206 GDP growth forecast unchanged at 4.6% as domestic demand supports expansion
Singapore telecom regulator suspends review of M1, Simba merger

Others Also Read